Updated:
HeartFlow
HeartFlow uses AI to turn cardiac CT scans into non-invasive diagnostics for coronary artery disease, now deployed in over 800 hospitals globally.
HeartFlow
HeartFlow was founded in 2007 by Charles Taylor, a former Stanford professor who spent years building computational models of blood flow. The company sits at the intersection of medical imaging and deep learning, using algorithms trained on thousands of patient-specific geometries to create a 3D model of the coronary arteries from a standard CT angiogram. The wealth backing the company comes not from a single family but from deep biotech and crossover investors, including Baillie Gifford, Capricorn Investment Group, and Janus Henderson. The company's core intellectual property is its FFR-CT Analysis, a diagnostic that measures fractional flow reserve without threading a wire into a patient's artery. This allows cardiologists to determine whether a stenosis is functionally significant and requires stenting. HeartFlow's technology received FDA clearance in 2014 and is now deployed in over 800 hospitals globally, including regions such as North America, Japan, and the United Kingdom. The platform has been studied in landmark clinical trials, including the ADVANCE registry of over 5,000 patients, which demonstrated its ability to safely reduce unnecessary invasive angiograms. HeartFlow operates as a venture-backed commercial-stage company, having closed a $215 million Series F round in April 2023 (per the firm's official communications, April 2023). The company employs over 600 professionals across offices in Mountain View, Austin, London, and Tokyo. Its technology is integrated into clinical pathways at health systems such as Imperial College Healthcare NHS Trust in the UK. In July 2024, the company announced that John Farquhar, a former Medtronic and Abbott executive, had joined as CEO to lead the next phase of commercial expansion (per HeartFlow press release, July 2024). HeartFlow's structural differentiator is its role as a deeply regulated clinical diagnostics manufacturer masquerading as an AI company. Unlike most venture-backed AI startups, HeartFlow's product is a Class II medical device requiring FDA premarket clearance and 510(k) amendments for each new algorithm version. This regulatory moat, combined with patient-specific reimbursement codes from payers like Medicare, creates a procurement cycle that resists the churn of pure software vendors. The company's relationship with its hospital clients is not a SaaS subscription but a clinical service trusted with life-or-death decisions, making switching costs enormous.
General information
Firm type
Asset Manager
Year founded
2007
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Mountain View
Corporate office
Mountain View, CA, United States
Additional offices
Austin, TX · London, UK · Tokyo, Japan
Principals
Charles A. Taylor
Founder & Chief Technology Officer
John Farquhar
Chief Executive Officer
Campbell Rogers
Chief Medical Officer
Sector focus
Frequently asked questions
Who runs investment and strategic decisions at HeartFlow?
HeartFlow is a venture-backed private company, not a family office or asset manager. Strategic and investment decisions are led by CEO John Farquhar and the board of directors, which includes representatives from major investors such as Baillie Gifford and Capricorn Investment Group. As a clinical-stage company, the FDA clearance pathway and clinical advisory board also heavily influence product and market strategy.
What is HeartFlow's core technology, and how is it differentiated?
HeartFlow's FFR-CT Analysis uses deep learning and computational fluid dynamics to non-invasively calculate fractional flow reserve from a standard coronary CT angiogram. It is the only FDA-cleared platform that provides patient-specific 3D coronary models to help clinicians decide whether a patient needs an invasive angiogram or stent. Competitors like CathWorks offer similar wire-free FFR, but HeartFlow's largest differentiator is its massive clinical-trial dataset, including the ADVANCE registry of over 5,000 patients.
How does HeartFlow's revenue model work with hospitals and payers?
HeartFlow generates revenue per analysis performed, and the procedure is covered by Medicare and a growing number of commercial payers through a specific CPT Category I code. This is not a typical enterprise software sale; it is a medical service claim paid per patient scan. Adoption is driven by positive clinical evidence and hospital formulary decisions, which creates a long sales cycle but very sticky recurring revenue once integrated into the cardiac care pathway.
Which cardiology societies have endorsed HeartFlow's approach?
HeartFlow's technology has received endorsements from major cardiology guidelines, including the American College of Cardiology and American Heart Association guidelines for chest pain evaluation. The UK's National Institute for Health and Care Excellence also issued positive guidance supporting the use of FFR-CT for patients with stable chest pain. These endorsements are a critical factor in payer coverage and hospital adoption.
What investment does HeartFlow hold in its competitors, and how does the competitive landscape look?
HeartFlow's primary direct competitor is CathWorks, which offers a competing FFR-angio system and has a co-marketing agreement with Medtronic. While HeartFlow was an early investor in CathWorks, the companies now compete directly in the non-invasive coronary physiology market. Other tangential competition comes from traditional pressure-wire FFR manufacturers like Abbott and Philips, although HeartFlow positions itself as a first-line gatekeeper tool to avoid those invasive procedures entirely.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: